| VERICEL CORP. |
| USA |
| Gesundheit |
| US92346J1088 / A12FU4 |
| ATQP (Frankfurt) / VCEL (NASDAQ) |
| FRA:ATQP, ETR:ATQP, ATQP:GR, NASDAQ:VCEL |
| - |
| https://www.vcel.com/ |
|
Vericel Corporation is a commercial-stage biopharmaceutical company focused on advanced cell therapies and specialty biologics for sports medicine and severe burn care. Vericel develops, manufactures, and markets products that support the repair of d..
>Volltext.. |
| 1846.04 Mio. EUR |
| 1786.87 Mio. EUR |
| 272.59 Mio. EUR |
| 27.72 Mio. EUR |
| 21.55 Mio. EUR |
| 0.43 EUR |
| 84.16 Mio. EUR |
| 111.56 Mio. EUR |
| 62 Mio. EUR |
| 3.09 |
| 26.82% |
| 251.53% |
| - |
| - |
| - |
| - |
| VERICEL, AASTROM |
| 05.11.26 |
|